Enantioseparation and quality control of biperiden in pharmaceutical formulations by capillary electrophoresis [An article from: Analytica Chimica Acta]

This digital document is a journal article from Analytica Chimica Acta, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
An original capillary electrophoretic method has been developed and applied for the enantioselective analysis of the antiparkinson drug biperiden in pharmaceutical formulations, using a modified cyclodextrin as the chiral selector. Baseline enantioseparation of the racemic compound was achieved in less than 7min using an uncoated fused silica capillary (50@mm i.d. and 48.5, 40.0cm, total and effective length, respectively), filled with a background electrolyte consisting of a 50mM phosphate buffer at pH 3.5 supplemented with 3% (w/v) @b-cyclodextrin sulphate and applying a voltage of 20kV, reversed polarity. Samples were injected by pressure (50mbar, 90s) at the cathodic end of the capillary and detection wavelength was 195nm (bandwidth: 10nm). A simple and fast pre-treatment procedure allowed the complete extraction of the drug from commercial formulations (sustained release tablets and ampoules for injections) without any interference from the matrix. Good linearity was found in the 1-50@mg/mL concentration range; the limit of quantitation was 1@mg/mL and the limit of detection was 0.4@mg/mL. Precision and accuracy were good, with R.S.D. values always lower than 2.8% and a mean recovery value of 101.1%. The method was suitable for the quality control of biperiden in commercial formulations.